リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer : A Case Report.」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer : A Case Report.

KUBOTA Shigehisa 80759118 KAGEYAMA Susumu 50378452 0000-0001-7150-647X NAGASAWA Masayuki 30750525 WADA Akinori 90750539 IKARI Ryo 70804293 TOMITA Keiji 30640148 YOSHIDA Tetsuya 60510310 NARITA Mitsuhiro 00263046 KAWAUCHI Akihiro 90240952 滋賀医科大学

2021.07.05

概要

BACKGROUND:
Cabazitaxel is a second-generation taxane approved for patients with metastatic castration-resistant prostate cancer (CRPC). Although cabazitaxel improves overall survival when used following docetaxel chemotherapy, duration of the clinical response is relatively short, and few patients achieve a long-term response.

CASE REPORT:
A 71-year-old man with prostate adenocarcinoma with an initial prostate-specific antigen (PSA) level of 4956 ng/ml, Gleason score 4+5 and cTxN0M1b was referred to our department for treatment. Several therapeutic approaches, including androgen deprivation therapy, with a combination of bicalutamide and a luteinizing hormone-releasing hormone analogue, and 4 sequential hormonal therapies including flutamide, estramustine, enzalutamide, and abiraterone, all failed to prevent disease progression. Subsequently, after 5 cycles of docetaxel chemotherapy were also ineffective, cabazitaxel chemotherapy at a dose of 20 mg/m² together with prednisone and pegfilgrastim was initiated. The patient developed grade 4 thrombocytopenia during the first 4 cycles, and the dosage of cabazitaxel had to be tapered to 12.5 mg/m² by the fifth cycle. In subsequent cycles, the treatment was continued without grade 4 thrombocytopenia or any other toxicities ³grade 3. The patient achieved a long-term clinical response over 4 years and his PSA level continued to decrease, from 29.8 ng/ml at treatment initiation to a nadir of 2.0 ng/ml after the 60th cycle.

CONCLUSIONS:
The present case is a rare example of a sustained response to low-dose cabazitaxel, and suggests its potential as a treatment option for metastatic CRPC patients. In our patient, this approach achieved a good clinical response with manageable toxicity over the long term.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J Clin. 2019;69:7-34

2. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract. 2011;65:1180-92

3. Heindenreich A, Bastian PL, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467-79

4. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised pen-label trial. Lancet. 2010;376:1147-54

5. Mukai H, Takahashi S, Nozawa M, et al. Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2014;73:703-10

6. Nozawa M, Mukai H, Takahashi S, et al. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol 2015;20:1026-34

7. Van Soest RJ, Nieuweboer AJM, De Morree ES, et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2015;51:2562-69

8. Kosaka T, Hongo H, Watanabe K, et al. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2018;82:1061-66

9. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009. https://ctep.cancer.gov/protocoldevelopment/ electronic_applications/ctc.htm#ctc_40

10. Center for Drug Evaluation and Research: NDA 20-1023 SUPPLEMENT APPROVAL FULFILLMENT OF POSTMARKETING REQUIREMENTS: Cabazitaxel. Updated 2017. https://www.accessdata.fda.gov/drugsatfda_docs/ label/2017/201023s019lbl.pdf

11. Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III STUDY COMPARING A REDUCED DOSE OF Cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017;35:3198-206

12. Suzuki K, Matsubara N, Kazama H, et al. Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: Results of a Japanese post-marketing surveillance study. Jpn J Clin Oncol. 2019;49:1157-68

13. Di Lorenzo G, Buonerba C, De Placido S. Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. Anticancer Drugs. 2015;26:236-39

14. Pal SK, Stein CA. Prolonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2012;10:274-76

15. Noronha V, Joshi A, Prabhash K. Beyond ten cycles of cabazitaxel for castration-resistant prostate cancer. Indian J Cancer. 2014;51:363-65

16. Atag E, Semiz HS, Kazaz SH, et al. Response to cabazitaxel beyond 20 cycles in a patient with penile metastasis of prostate cancer: A case report. Urol J. 2017;14:2985-88

17. Pean E, Demolis P, Moreau A, et al. The European medicines agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: Summary of the scientific assessment of the committee for medical products for human use. Oncologist. 2012;17:543-49

18. De Morree ES, Bottcher R, van Soest RV, et al. Loss of SCLO1B3 drives taxane resistance in prostate cancer. Br J Cancer. 2016;115:674-81

19. Belderbos BPS, With M, Singh RK, et al. The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2020;85:547-53

参考文献をもっと見る